Latest Blogs

Frank L. Meyskens, MD
Nov 28, 2022
Meeting the Navajo: The Impact of Culturally Sensitive Care
I began my medical career in Arizona, where I received an early lesson in the importance of cultural sensitivity thanks to members of the Navajo Nation from the Four Corners region.
Nagi S. El Saghir, MD, FASCO, FACP
Nov 17, 2022
Breast Cancer Awareness Campaigns Are Back in Full Action!
After two years of limited activity during the COVID-19 pandemic, October Breast Cancer Awareness Month returned in 2022 with a variety of traditional and innovative activities worldwide.
International Perspectives
Nov 10, 2022
Advancing Research in Resource-Limited Settings: Don’t Be Afraid to Dream Big
"Cancer research relevant to LMICs is a necessity, not a luxury," writes Dr. Khalid El Bairi, and early-career oncologists in LMIC settings can advance cancer research in their communities.
ASCO Commentary
Nov 10, 2022
Vote in the ASCO Election; Ballot Closes December 6
ASCO president Dr. Eric P. Winer and Nominating Committee chair Dr. Beverly S. Mitchell call upon all eligible voters to make their voices heard in the ASCO election.
Subscribe to this column

Clifford A. Hudis, MD, FACP, FASCO

Clifford A. Hudis, MD, FACP, FASCO, is the CEO of ASCO, executive vice chair of Conquer Cancer, the ASCO Foundation, and chair of CancerLinQ. Prior to these roles, he served as chief of the Breast Medicine Service and an attending physician at Memorial Sloan Kettering Cancer Center and as a professor in the Department of Medicine at Weill Cornell Medical College. He is a past president of ASCO. His research interests include all areas of care related to breast cancer, with a focus on the development of novel systemic therapies and prevention interventions related to obesity and inflammation. Follow Dr. Hudis on Twitter @CliffordHudis.

Disclosure.

May 20, 2019
The Impact of Utilization Management on Patients and Practices: A Conversation with Dr. Jeffery Ward
Dr. Ward and I discuss the policies that public and private insurers use to control the use of anticancer drug therapies, such as prior authorization requirements, restrictive formularies, step therapy, or fail first requirements, and specialty specific tiers.
Mar 26, 2019
Exclusive Interview: NCI Director Dr. Ned Sharpless Discusses the Future of Cancer Clinical Trials
Dr. Sharpless joined me to talk about pediatric cancer research, clinical trial methodology, eligibility criteria, and more.
Mar 11, 2019
Losing a Board Member: 5 Lessons From the Life of Dr. Arti Hurria
For many of us not a day has gone by without some reminder of Arti, but last week brought it all back into sharp focus as I was asked to talk about the role we at ASCO played in her career during a symposium in her honor.
Feb 07, 2019
Exclusive Interview: FDA Commissioner Dr. Scott Gottlieb Talks Drug Pricing, Expanded Access, and Tobacco Control
Dr. Gottlieb discusses the FDA's efforts to increase overall efficiency by updating or modernizing aspects of our clinical trials conduct and expediting the end-to-end drug development process, as well as controlling the next generation of tobacco products.
Feb 01, 2019
Reflections on World Cancer Day 2019: The Challenge of “I Will”
What will each of us do, going forward, to further confront and reduce the global burden of cancer? For us at ASCO, the challenge will be answered through our mission pillars: education, research, and quality.
Jan 28, 2019
What You Need to Know About the Final 2019 Medicare Physician Fee Schedule and Quality Payment Program Rule
Editor’s note: Dr. Hudis hosts the ASCO in Action Podcast, which focuses on policy and practice issues affecting providers and patients. An excerpt of a recent episode is shared below; it has been edited for length and clarity.

Pages